The transcription factor Ets-1 is implicated in various physiological processes and invasive pathologies. We identified a novel variant of ets-1, ets-1D(III-VI), resulting from the alternative splicing of exons III to VI. This variant encodes a 27 kDa isoform, named Ets-1 p27. Ets-1 p27 lacks the threonine-38 residue, the Pointed domain and the transactivation domain, all of which are required for the transactivation of Ets-1 target genes. Both inhibitory domains surrounding the DNA-binding domain are conserved, suggesting that Ets-1 p27, like the full-length Ets-1 p51 isoform, is autoinhibited for DNA binding. We showed that Ets-1 p27 binds DNA in the same way as Ets-1 p51 does and that it acts both at a transcriptional and a subcellular localization level, thereby constituting a dual-acting dominant negative of Ets-1 p51. Ets-1 p27 blocks Ets-1 p51-mediated transactivation of target genes and induces the translocation of Ets-1 p51 from the nucleus to the cytoplasm. Furthermore, Ets-1 p27 overexpression represses the tumor properties of MDA-MB-231 mammary carcinoma cells in correlation with the known implication of Ets-1 in various cellular mechanisms. Thus the dual-acting dominant-negative function of Ets-1 p27 gives to the Ets-1 p27/Ets-1 p51 ratio a determining effect on cell fate.
Introduction
Splicing of intronic sequences is a physiological cellular mechanism implicated in RNA maturation. During this process, exonic sequences can be alternatively spliced, generating either nonsense mRNAs, which will be degraded, or mature mRNAs, which can encode proteins with different structures and properties, called isoforms (Smith and Valcarcel, 2000; Stamm et al., 2005) . Alternative splicing of mRNA precursors can be modulated in a spatiotemporal manner and can participate in the regulation of gene functions (Shin and Manley, 2004) . Alternative splicing occurs in numerous members of the Ets family of transcription factors such as GABPa (O'Leary et al., 2005) , Tel (Sasaki et al., 2004) , Spi-B (Ray-Gallet et al., 1996) , Ets-1 (Baillat et al., 2002) , Fli-1 (Sarrazin et al., 2000) , ER81 (Coutte et al., 1999) , Erg (Hewett et al., 2001) , ESE-1 (Lei et al., 2007) , ELF-1 (Cho et al., 2004) , Elk-1 (Araud et al., 2007) and ER-71 (De Haro and Janknecht, 2005) .
The Ets family is characterized by a well-conserved DNA-binding domain (DBD), called the ETS domain, and recognizes specific DNA elements, called Etsbinding sites (EBS), found in the promoters of target genes. The founding member of this family, Ets-1, is involved in numerous cellular mechanisms such as proliferation (de Nigris et al., 2001; Higuchi et al., 2007) , differentiation (Lulli et al., 2006; John et al., 2007) , migration (Kita et al., 2001) , invasion (Taniguchi et al., 2007) and apoptosis (Teruyama et al., 2001) . However, when overexpressed, Ets-1 is partly responsible for the development of invasive pathologies such as rheumatoid arthritis (Redlich et al., 2001) , glomerulonephritis (Raffetseder et al., 2004) or cancers (Dittmer, 2003) . Ets-1 is now considered as a marker of poor prognosis in numerous cancers (Nakayama et al., 2001; Alipov et al., 2005; Katayama et al., 2005) .
The activity of Ets-1 is tightly controlled, especially at the DNA-binding level, to ensure a specific biological action. Indeed, Ets-1 is autoinhibited for DNA binding due to the presence of two inhibitory domains surrounding and interacting with its DBD (Lee et al., 2005) . To counteract autoinhibition and improve DNA binding, Ets-1 interacts with partners, enabling their cooperative binding to adjacent DNA elements (Pufall and Graves, 2002) . Ets-1 can also counteract its autoinhibition on its own by binding to a particular organization of palindromic EBS spaced by 4 bp, as in the stromelysin-1 matrix metalloproteinase and the p53 oncosuppressor promoters (Wasylyk et al., 1991; Baillat et al., 2002 Baillat et al., , 2009 . Two molecules of Ets-1 cooperatively bind to the EBS palindrome, thereby forming an Ets-1/DNA/Ets-1 ternary complex, which is critical for full transactivation (Baillat et al., 2002) .
Until now, only two isoforms of Ets-1 have been described: the full-length protein Ets-1 p51 (usually called Ets-1) and the isoform encoded by the ets-1DVII alternative splicing variant Ets-1 p42 (Koizumi et al., 1990) . This latter variant lacks exon VII, which encodes, in particular, the N-terminal inhibitory domain. Therefore, Ets-1 p42 is not autoinhibited and presents different DNA-binding and transcriptional properties from the full-length Ets-1 p51 protein (Fisher et al., 1994; Baillat et al., 2002) . Thus, Ets-1 p51 and Ets-1 p42 regulate different target genes, illustrating regulation of Ets-1 function through alternative splicing (Li et al., 1999; de Nigris et al., 2001; Taniguchi et al., 2007) .
In this study, we identified a novel variant of ets-1, named ets-1D(III-VI), which results from the alternative splicing of exons III to VI. This variant encodes a 27 kDa isoform, named Ets-1 p27. By characterizing the molecular and cellular properties of Ets-1 p27, we show that Ets-1 p27 is the first natural Ets-1 dominant negative that acts both at a transcriptional and a subcellular localization level and which represses the tumoral properties of invasive mammary carcinoma cells.
Results

ets-1D(III-VI)
is a novel ets-1 variant expressed in a tissue-specific manner A novel ets-1 variant was identified by reverse transcription (RT)-PCR using flanking primers in HIG-82 rabbit synovial fibroblastic cells in addition to transcripts corresponding to full-length ets-1 and exon-VII-deleted ets-1DVII (data not shown). The complete coding sequence of this variant, which is available in GenBank under accession number EU939724, demonstrates that it results from the alternative splicing of exons III to VI (Figure 1a, left) . Therefore, this novel ets-1 variant was called ets-1D(III-VI). Its expression was confirmed in HIG-82 cells by RT-PCR using two other primer pairs (Figure 1a) : the pair 1, composed of primers designed in exon A and exon VII and the pair 2, composed of primers located at the ets-1D(III-VI) splicing junction and in exon VII.
Using this two primer pairs, we showed by RT-PCR that both ets-1 and ets-1D(III-VI) transcripts were synthesized in HIG-82 cells, MG-63 human osteosarcoma cells and MDA-MB-231 invasive human mammary adenocarcinoma cells (Figure 1b) . The complete coding sequence of the human ets-1D(III-VI) variant in MDA-MB-231 cells was determined and is available in GenBank under accession number AY943926.
Reverse transcription-PCR performed on RNAs from human mammary adenocarcinomas (Figure 1c , lanes 1-3) and PCR on cDNA from a human mammary tissue library (Figure 1c , lane 4) revealed that the two transcripts were expressed in tumor mammary tissues, but not in normal tissues. Next, cDNA libraries of human fetal and adult tissues were analysed by PCR (Figure 1d ). Both ets-1 and ets-1D(III-VI) were detected in all fetal tissues tested, but varied with tissue type in adult tissues. Indeed, both ets-1 and ets-1D(III-VI) were expressed in spleen, thymus, placental and ovarian tissues, but neither in brain nor kidney tissues. Thus, ets-1D(III-VI) was expressed along with full-length ets-1 in some tissue and their ratio depended on cell and tissue types, suggesting a tissue-dependent effect of ets-1D(III-VI) on ets-1 properties.
ets-1D(III-VI) variant encodes Ets-1 p27, a novel Ets-1 isoform The novel ets-1D(III-VI) variant gives rise to a 225-amino-acid Ets-1 protein, which lacks the threonine-38 (Thr38) residue as well as the Pointed (PNT) and transactivation (TAD) domains, all of which are required for the transactivation of Ets-1 target genes (Jayaraman et al., 1999; Seidel and Graves, 2002; Foulds et al., 2004) . However, it conserves the DBD flanked by the two inhibitory domains. Given its apparent molecular mass of 27 kDa, this isoform was called Ets-1 p27, in contrast to full-length Ets-1 that has a mass of 51 kDa (Figure 2a ). Western blot analysis of native and ets-1D(III-VI) cDNA-transfected HIG-82 cells, using the C-20 anti-Ets-1 antibody directed against Ets-1 DBD, showed the presence of a 27 kDa endogenous protein ( Figure 2b , lane 1), which migrates exactly the same way as exogenous Ets-1 p27 does ( Figure 2b , lane 2). Thus, Ets-1 p27 was endogenously expressed in HIG-82 cells. Furthermore, its intensity was roughly equivalent to that of Ets-1 p42. A higher molecular mass protein was also detected in transfected HIG-82 cells ( Figure 2b , lane 2). This protein probably corresponds to post-translationally modified Ets-1 p27, which was only weakly observed in native cells due to its low expression level.
Expression of Ets-1 p27 was then assessed in various cell lines by western blot using either the C-20 anti-Ets-1 antibody directed against Ets-1 DBD or a specific anti-Ets-1 p27 antibody, directed against the Ets-1 p27 alternative splicing junction (Figure 2c Ets-1 p27 binds to the EBS palindrome of the stromelysin-1 promoter in the same way as Ets-1 p51 does and competes with Ets-1 p51 for binding We then determined whether Ets-1 p27 was autoinhibited like Ets-1 p51 and whether autoinhibition is counteracted by cooperative binding to the palindromic EBS of the stromelysin-1 promoter. Electrophoretic mobility shift assays (EMSAs) were carried out using Ets-1 p51 or Ets-1 p27 recombinant proteins and 30-mer (Table 1; Figure 3a ). As expected, results showed that Ets-1 p51 and Ets-1 p27 formed ternary complexes with the wild-type EBS palindrome (indicated by arrows 1 and 2 in Figure 3a , lanes 1 and 5), whereas mutation of one (M1, M2) or both (M1M2) EBS prevented both isoforms from forming DNA/protein complexes ( Figure 3a , lanes 2-4 and 6-8). In both cases, these complexes were disrupted by an 800 Â molar excess of WT non-labeled DNA probe ( Figure 3b , lanes 2 and 5), but not by an 800 Â molar excess of M1M2 non-labeled DNA probe (Figure 3b , lanes 3 and 6). This confirmed the complexes' specificity to the EBS palindrome.
Surface plasmon resonance (SPR) measurement experiments were then carried out using Biacore technology (Figure 3c ). For both Ets-1 p27 and Ets-1 p51, the measured resonance unit (RU) signal corre- Right: single-strand cDNAs were synthesized from HIG-82 total RNAs and ets-1 cDNAs were amplified by PCR using the two primer pairs (pairs 1 and 2) indicated in the left. Amplified PCR products, which correspond to ets-1 and ets-1D(III-VI), were resolved on a 2% agarose gel stained with ethidium bromide and are indicated by arrows related to the scheme. (b) RT-PCR analysis of different cell lines. RNAs from HIG-82, MG-63 and MDA-MB-231 cells were retrotranscribed and ets-1 cDNAs were amplified by PCR using the two primer pairs described in (a). Amplification of glyceraldehyde-3-phosphate dehydrogenase (gapdh) with specific primers was used as a loading control and amplification without template as a negative control (NC). (c) Analysis of tumor and normal mammary tissues by RT-PCR and PCR. RNAs extracted from human mammary adenocarcinomas (lanes 1-3) and cDNAs from a normal mammary tissue library (lane 4) were amplified by RT-PCR and PCR, respectively, as described in (b). (d) Analysis of fetal and adult human tissues by PCR. cDNAs from fetal and adult human tissue libraries were amplified by PCR as described in (b).
Ets-1 p27, a dual-acting Ets-1 dominant negative C Laitem et al sponding to binding to the WT probe was higher than the sum of those obtained with M1 and M2 probes ( Figure 3c , indicated by dotted line M1 þ M2). Ets-1 p27 thus binds cooperatively to the EBS palindrome of the stromelysin-1 promoter in the same way as Ets-1 p51 does.
Next, we assessed the ability of Ets-1 p27 to compete with Ets-1 p51 for binding. For this purpose, EMSA experiments were carried out using the 30-mer 32 P-labeled WT DNA probe (Table 1 ) and various Ets-1 p51/Ets-1 p27 ratios ( Figure 3d ). Results showed that the Ets-1 p51/DNA/Ets-1 p51 ternary complex ( Figure 3d , lane 1) was disrupted in a dose-dependent manner in the presence of Ets-1 p27 ( Figure 3d , lanes 2-4), leading to the formation of an Ets-1 p27/DNA/ Ets-1 p27 ternary complex ( Figure 3d , lane 5). This disruption was accompanied by the formation of an intermediate migrating complex (indicated by arrow i), composed of one molecule of each isoform. Thus, the novel Ets-1 p27 isoform competes with Ets-1 p51 for binding to the EBS palindrome of the stromelysin-1 promoter.
Ets-1 p27 is a dominant negative for Ets-1 p51 and other autoinhibited Ets proteins transcriptional transactivation To verify if Ets-1 p27 can block Ets-1 p51 transcriptional properties, luciferase transactivation assays were performed with the stromelysin-1 promoter (WT or M1M2) using increasing concentrations of Ets-1 p27 with or without Ets-1 p51 (Figure 4a ). HEK-293 cells were used because they lack endogenous Ets-1, allowing us to monitor the expression of the different Ets-1 isoforms. It appeared that Ets-1 p27 was unable to activate the stromelysin-1 promoter on its own ( Figure 4a , lanes 1-8). Nevertheless, it repressed in a dose-dependent manner the activation of the WT promoter mediated by Ets-1 p51 ( Figure 4a , lanes 9-12). This was mediated through the EBS palindrome, because EBS mutations abrogated any Ets-1 p27 effects ( Figure 4a , lanes 13-16). Thus, Ets-1 p27 constitutes a dominant-negative isoform for Ets-1 p51 transactivation of the stomelysin-1 promoter. Because autoinhibited Ets-2 and PEA-3 proteins also activate this promoter through the EBS palindrome (Buttice and Kurkinen, 1993; Higashino et al., 1995) , luciferase transactivation assays were also carried out, as described above, using Ets-2 ( Figure 4b ) and PEA-3 ( Figure 4c ) as transcriptional activators. Results showed that Ets-1 p27 acts also as a dominant negative for Ets-2 and PEA-3 transactivation of the stromelysin-1 promoter. Furthermore, we demonstrated that Ets-1 p27 repressed in a dose-dependent manner the synergistic activation of the collagenase-1 promoter induced by Ets-1 p51 and the c-Jun/c-Fos (AP-1) complex, through the 12-O-tetradecanoylphorbol-13-acetate (TPA) oncogene response unit, composed of an EBS adjacent to an AP-1 site (see Supplementary Information, Figure S1 and Table S1 ). Thus, Ets-1 p27 is also a dominant negative for Ets-1 p51 transactivation of target promoters mediated through combinatorial regulation with interaction partners.
Ets-1 p27 delocalizes Ets-1 p51 from the nucleus to the cytoplasm To mediate its transcriptional dominant-negative function, Ets-1 p27 must be coexpressed with Ets-1 p51 in and Jurkat (lane 5) were analysed by western blot using the C-20 anti-Ets-1 antibody and a specific anti-Ets-1 p27 antibody directed against Ets-1 p27 alternative splicing junction. 
Sequences of the À223/À193 EBS palindrome of the stromelysin-1 promoter and its mutants. The EBS core sequences are represented as boldface letters in the sequence. Mutations are boxed.
Ets-1 p27, a dual-acting Ets-1 dominant negative C Laitem et al the nucleus. To determine the subcellular localization of Ets-1 p27, immunofluorescence assays were performed on HEK-293 cells exogenously expressing Ets-1 p51 or Ets-1 p27 (Figure 5a ). Results confirmed the nuclear localization of Ets-1 p51 ( Figure 5a , lane 2) and showed a nuclear and cytoplasmic expression of the novel Ets-1 p27 isoform (Figure 5a , lane 3). Thus, not only is Ets-1 p27 present in the nucleus but its presence in the cytoplasm suggests that Ets-1 p27 may sequestrate Ets-1 p51 partners in the cytoplasm or directly delocalize Ets-1 p51 from the nucleus to the cytoplasm.
To test this hypothesis, we performed colocalization experiments using Ets-1 p51 fused to a Flag-tagged and Ets-1 p27 fused to the enhanced green fluorescent protein (EGFP). Immunofluorescence experiments performed on HEK-293 cells expressing Flag-Ets-1 p51 (Figure 5b ) or EGFP-Ets-1 p27 (Figure 5c ) confirmed that tags did not alter protein subcellular localization of either isoform. Vector used to encode EGFP-Ets-1 p27 intrinsically expressed EGFP detected in control ( Figure 5c , lane 1). Colocalization experiments showed that in the presence of Ets-1 p27, Ets-1 p51 was mainly 1-3) or Ets-1 p27 (lanes 4-6) (4 pmol) was incubated with WT 32 P-labeled DNA probe (0.5 ng) in the absence (lanes 1 and 4) or presence of unlabeled competitors (WT 800 Â , lanes 2 and 5 or M1M2 800 Â , lanes 3 and 6). For both experiments, DNA/protein complexes were separated by electrophoresis in a 5% nondenaturing polyacrylamide gel. Free probes were detected at the bottom of the gel. Arrows indicate ternary complexes (arrow 1, Ets-1 p51/DNA/Ets-1 p51 and arrow 2, Ets-1 p27/DNA/Ets-1 p27). with an increase amount of Ets-1 p27 (0-15 pmol) (lanes 2-4) was incubated with WT 32 P-labeled DNA probe (0.5 ng). DNA/protein complexes were separated by electrophoresis in a 5% nondenaturing polyacrylamide gel. Arrows 1 and 2 are described above and arrow i corresponds to Ets-1 p51/DNA/Ets-1 p27 intermediate ternary complex.
Ets-1 p27, a dual-acting Ets-1 dominant negative C Laitem et al Figure 4 Ets-1 p27 acts as a dominant negative for transactivation of the stromelysin-1 promoter mediated by autoinhibited Ets-1 p51, Ets-2 and PEA-3 through the Ets-binding sites (EBS) palindrome. (a) Effect of Ets-1 p27 on the basal or Ets-1 p51-induced stromelysin-1 promoter activity. pGL3 luciferase reporter constructs (100 ng; wild-type (WT), lanes 1-4 and 9-12 or M1M2, lanes 5-8 and 13-16) were transfected into HEK-293 cells at a 50-80% confluence in the absence (À) or in the presence ( þ ) of Ets-1 p51 expression vector (100 ng; lanes 9-16) and with increasing amounts of Ets-1 p27 expression vector (0-100 ng; lanes 2-4, 6-8, 10-12 and 14-16). (b) Effect of Ets-1 p27 on the Ets-2-induced stromelysin-1 promoter activity. pGL3 luciferase reporter constructs (100 ng; WT, lanes 1-5 or M1M2, lanes 6-10) were transfected into HEK-293 cells at a 50-80% confluence with Ets-2 expression vector (100 ng; lanes 2-5 and 7-10) and an increasing amount of Ets-1 p27 expression vector (0-100 ng; lanes 3-5 and 8-10). (c) Effect of Ets-1 p27 on the PEA3-induced stromelysin-1 promoter activity. pGL3 luciferase reporter constructs (100 ng; WT, lanes 1-5 or M1M2, lanes 6-10) were transfected into HEK-293 cells at a 50-80% confluence with PEA3 expression vector (100 ng; lanes 2-5 and 7-10) and an increasing amount of Ets-1 p27 expression vector (0-100 ng; lanes 3-5 and 8-10). In all experiments, luciferase activity, measured 48 h after transfection, is expressed as the percentage of WT construct activity induced by Ets-1 p51, Ets-2 or PEA3, respectively. Cell lysates (30 mg total proteins) were analysed by western blot using different antibodies (see Materials and methods). Results are the average of three experiments performed in triplicate. lanes 1 and 2) or Flag-Ets-1 p51 (500 ng, lanes 3-5) pcDNA3 expression vector, and with EGFP (500 ng, lanes 1 and 3) or EGFP-Ets-1 p27 (500 ng, lanes 2-5) pEGFP-C1 expression vectors. Proteins were detected as described in (b) and (c). (e) Endogenous effect of Ets-1 p27. MDA-MB-231 cells stably expressing Flag-Ets-1 p27 (lane 2) or not (lane 1) were fixed with paraformaldehyde and treated with rabbit C-20 anti-Ets-1 antibody followed by goat anti-rabbit antibody coupled to Alexa Fluor 594. In all experiments, nuclei were visualized with Hoechst stain. Cells were examined by fluorescence microscopy at Â 100 magnification. Scale bar ¼ 20 mm.
Ets-1 p27, a dual-acting Ets-1 dominant negative C Laitem et al detected in the cytoplasm instead of the nucleus (Figure 5d , lanes 4-5), but EGFP alone did not have this effect on Ets-1 p51 (Figure 5d, lane 3) . Thus, Ets-1 p27 induces Ets-1 p51 translocation from the nucleus to the cytoplasm. The capacity of Ets-1 p27 to delocalize endogenous Ets-1 p51 was then tested in MDA-MB-231 cells, which express the three Ets-1 isoforms. In control MDA-MB-231 cells, Ets-1 proteins were mainly detected in the nucleus, but weak signals were also observed in the cytoplasm (Figure 5e , lane 1). This cytoplasmic signal probably corresponded to endogenous Ets-1 p27 or Ets-1 p51 delocalized by the endogenous Ets-1 p27 isoform. In MDA-MB-231 cells stably overexpressing Ets-1 p27, Ets-1 proteins were
Ets-1 p27, a dual-acting Ets-1 dominant negative C Laitem et al clearly transferred from the nucleus to the cytoplasm ( Figure 5e , lane 2). Taken together, these experiments unambiguously demonstrate that an increase in the Ets-1 p27/Ets-1 p51 ratio induces the delocalization of endogenous Ets-1 protein from the nucleus to the cytoplasm.
Ets-1 p27 overexpression represses the tumoral properties of MDA-MB-231 cells Owing to the dual-acting dominant-negative function of Ets-1 p27 and the known implication of Ets-1 p51 in various cellular processes, we explored the effect of the increase of Ets-1 p27 expression on endogenous Ets-1 p51 properties. As Ets-1 isoforms are expressed in cells that have invasive properties, Ets-1 p27 was stably overexpressed in invasive MDA-MB-231 mammary carcinoma cells by retroviral infection (Figure 6a , clones 2 and 3 indicated by 2 and 3, respectively) and compared to cells that did not overexpress Ets-1 p27 (Figure 6a , clone 1 indicated by 1). Phenotypic analysis of these clones showed that Ets-1 p27 overexpression (1) slowed down anchorage growth of MDA-MB-231 cells and induced the arrest of their proliferation at a lower confluent state (Figure 6b) , (2) reduced the number and the size of the colonies formed in soft agar ( Figure 6c ) and (3) repressed the cells' ability to digest the reconstituted basement membrane and migrate through the porous membrane of an invasion chamber (Figure 6d ). Taken together, these results demonstrate that an increase in the Ets-1 p27/Ets-1 p51 ratio represses the properties of proliferation, transformation and invasion of MDA-MB-231 cells. This effect appeared stronger in clone 3, where Ets-1 p27 expression was slightly higher, compared to clone 2 (Figure 6a ), suggesting a dose-dependent effect of Ets-1 p27. As a control of specificity, we also stably overexpressed Ets-1 p27 in noninvasive MCF-7 mammary carcinoma cells (data not shown), which do not endogenously express Ets-1 and some of its target genes such as stromelysin-1 and collagenase-1. However, we could not detect any effect of Ets-1 p27 on the phenotype of these cells (data not shown), suggesting that the Ets-1 p27 effect described in MDA-MB-231 cells may function mainly by counteracting endogenous Ets-1 properties. Moreover, RT-PCR analysis of the MDA-MB-231 clones treated with or without phorbol 12-myristate 13-acetate (PMA), a tumor inducer that increases ets-1 expression, showed that the overexpression of Ets-1 p27 induced a decrease in the mRNA levels of Ets-1 target genes such as stromelysin-1, gelatinase-B, uPA, p53 and p21, at basal and/or PMA-induced levels (Figure 6e) . Furthermore, the phenotypic results were corroborated by those obtained in vivo (Figure 6f ). Xenografts of MDA-MB-231 clones in nude mice by subcutaneous injection showed that the growth of the tumor formed by clones 2 and 3 was repressed compared to that of clone 1, as illustrated by the size of the tumor and the time it took for the tumor to double in volume. The repression of tumor growth was higher for clone 3 compared to clone 2, suggesting once again a dosedependent effect of Ets-1 p27 on MDA-MB-231 properties. Thus, overexpression of Ets-1 p27 in MDA-MB-231 cells reduces tumor growth.
Discussion
Although several variants of ets-1 were detected in human (Jorcyk et al., 1991) , only two isoforms have been described up to now: Ets-1 p51, the full-length protein and Ets-1 p42, an isoform lacking the exon-VII-encoding domain. In this study, we identified ets-1D(III-VI), a novel ets-1 variant resulting from the alternative splicing of exons III to VI. This variant, first identified in HIG-82 rabbit synovial fibroblastic cells, was detected in many human tissues known for expressing Ets-1 (Rowe and Propst, 1992; Maroulakou and Bowe, 2000; Takai et al., 2006 ; Figure 1 ). The relative ratio of both ets-1 and ets-1D(III-VI) varied with cell and tissue type, suggesting tissue-specific effects of ets-1D(III-VI).
This ets-1D(III-VI) variant encodes a 27 kDa isoform, named Ets-1 p27, the structure of which suggested a dominant-negative function (Figure 2) . Results of this study enable us to confirm this assumption and to propose a model in which Ets-1 p27 constitutes a dual-acting dominant negative for Ets-1 p51 (Figure 7 ). In this model, Ets-1 p27 acts both at a transcriptional level in blocking Ets-1 p51-mediated transactivation of target genes and at a subcellular localization level in inducing the translocation of Ets-1 p51 from the nucleus to the cytoplasm (Figure 7b) .
The DNA-binding and transcriptional properties of Ets-1 p27 were assessed on the EBS palindrome of the stromelysin-1 promoter, the regulation of which is well documented. The stromelysin-1 promoter is stimulated through this EBS palindrome by autoinhibited Ets-1 (Wasylyk et al., 1991) , Ets-2 (Buttice and Kurkinen, 1993) or PEA-3 (Higashino et al., 1995) . Here, we demonstrated that autoinhibited Ets-1 p27 competes with Ets-1 p51 for binding to the EBS palindrome of the stromelysin-1 promoter (Figure 3) , demonstrating its dominant-negative effect toward Ets-1 p51 binding (Figure 7b ). This competition implicates the formation of an intermediate Ets-1 p51/DNA/Ets-1 p27 ternary complex, suggesting that both isoforms interact with each other on the EBS palindrome of the stromelysin-1 promoter. Furthermore, Ets-1 p27 blocks, on the one hand, the transactivation of the stromelysin-1 promoter induced not only by Ets-1 p51 but also by Ets-2 and PEA-3 (Figure 4 ). This effect most likely arises owing to the formation of the Ets-1 p27 ternary complex, rendering the EBS inaccessible to other Ets activator factors. On the other hand, Ets-1 p27 blocks the synergistic transactivation of the collagenase-1 promoter induced by Ets-1 p51 and c-Jun/c-Fos complex (see Supplementary Information, Figure S1 ). In this context, the dominant-negative effect of Ets-1 p27 may result from its ability to replace Ets-1 p51 in the interaction with its partners (Figure 7b ). This is supported by the fact that the interaction of Ets-1 p51 with the AP-1
Ets-1 p27, a dual-acting Ets-1 dominant negative C Laitem et al complex is mediated through the DBD (Dittmer, 2003) , which is conserved in the structure of Ets-1 p27. Therefore, Ets-1 p27 may be able to interact with the AP-1 complex on the collagenase-1 promoter, effectively blocking Ets-1 p51-mediated transactivation.
Interaction with partners is crucial for counteracting Ets-1 p51 autoinhibition and, therefore, for Ets-1 p51 recruitment to target promoters. Given its structure, Ets-1 p27 should conserve Ets-1 p51 partner interactions that are mediated through the inhibitory were transferred to soft agar plates for incubation. After 2 weeks, the colony numbers were scored with a microscope and photographs were taken with a camera adapted to a microscope at Â 5 and Â 20 magnifications. Colony numbers were scaled to the colony number of clone 1, used as a reference and set to 100%. Results are the average of three experiments performed in triplicate. (d) Invasion assays. MDA-MB-231 clones (50 000 cells per well), added to a medium containing 0.1% fetal bovine serum, were placed in the invasion chamber and allowed to invade over a period of 16 h in an attractive medium containing 5% fetal bovine serum. Cells that had invaded were fixed, stained, scored and photographed through an inverted fluorescence microscope. The invasive cell number of clone 1 was used as a reference and set to 100%. Results are the average of three experiments performed in triplicate. (e) Reverse transcription (RT)-PCR analysis of MDA-MB-231 clones treated with or without phorbol 12-myristate 13-acetate (PMA). After 36 h starvation, MDA-MB-231 clones were incubated for 24 h in a medium containing 1 ng/ml PMA. RNAs of clones treated with or without PMA were then retrotranscribed and cDNAs were amplified by PCR using different primer pairs (see Materials and methods). Amplified PCR products were resolved on an agarose gel stained with ethidium bromide. Amplification of glyceraldehyde-3-phosphate dehydrogenase (gapdh) with specific primers was used as a loading control and amplification without template as a negative control (NC). Ets-1 p27, a dual-acting Ets-1 dominant negative C Laitem et al domains and the DBD. However, interactions implicating the PNT and TAD domains are probably abolished. Therefore, Ets-1 p27 may compete with Ets-1 p51 for only some of its target promoters. Furthermore, generation of a novel peptide sequence at the splicing junction of Ets-1 p27 suggests the existence of different interaction partners and, possibly, different target genes. Thus, Ets-1 p27 may act on selected target promoters, increasing its specificity and efficacy. Owing to its autoinhibition, to bind DNA and activate transcription, the nuclear Ets-1 p51 factor requires target promoters that have either palindromic Ets-binding sites (EBS) spaced by 4 bp to form the Ets-1 p51/DNA/Ets-1 p51 ternary complex or adjacent partner DNA elements to recruit Ets-1 p51 through interaction with partners. (b) Dual-acting dominant-negative function of Ets-1 p27.
(1) Dominant negative for transcription. Autoinhibited Ets-1 p27 binds DNA the same way as Ets-1 p51 does, and thereby prevents Ets-1 p51 from binding. Nevertheless, due to its lack of the Thr38 residue and the Pointed (PNT) and transactivation (TAD) domains, Ets-1 p27 has no transcriptional effect on the target promoters and effectively blocks Ets-1 p51-mediated transactivation. (2) Dominant negative for subcellular localization. Ets-1 p27 is able to delocalize Ets-1 p51 from the nucleus to the cytoplasm.
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In addition to its transcriptional dominant-negative effect, Ets-1 p27 is also shown to be localized ( Figure 5 ): (1) in the nucleus, required for the mediation of its transcriptional properties and (2) in the cytoplasm, leaving the possibilities open as to other functions. As illustrated by our model (Figure 7b) , we also demonstrated that Ets-1 p27 has the ability to delocalize Ets-1 p51 from the nucleus to the cytoplasm. Translocation of Ets-1 p51 has been described during the terminal differentiation of erythroid progenitors (Lulli et al., 2006) . When localized in the nucleus in these cells, Ets-1 p51 induces the expression of the GATA-2 gene, which effectively blocks differentiation. Therefore, the delocalization of Ets-1 p51 makes this transcription factor unavailable for the regulation of GATA-2. Translocation of Ets-1 p51 has also been described in a study performed on mouse thymocytes (Pognonec et al., 1990) . The stimulation of these cells with a calcium ionophore induces the phosphorylation of Ets-1 p51 on the exon-VII-encoded domain, which is then redistributed from the nucleus to the cytoplasm. This phosphorylation also reinforces Ets-1 p51 autoinhibition and, therefore, represses DNA binding (Cowley and Graves, 2000) . As Ets-1 p27 conserves the exon-VIIencoded domain, it may also be phosphorylated, thereby repressing DNA binding in response to calcium signaling. In this case, dominant-negative function of Ets-1 p27 may act preferentially through subcellular localization rather than through transcriptional effects. Thus, depending on the cellular signaling pathway, Ets-1 p27 may favor one or the other of its two dominant-negative functions.
Even if Ets-1 is mainly described as a nuclear factor (Kitange et al., 1999; Redlich et al., 2001; Li et al., 2007) , other studies have shown a cytoplasmic localization, in particular in breast (Mylona et al., 2006) , ovary (Takai et al., 2002) and endometrial (Takai et al., 2000) carcinomas as well as in quiescent endothelial cells (Valter et al., 1999) . In these studies, the different isoforms of Ets-1 could not be discriminated. However, we can speculate that the cytoplasmic localization of Ets-1 may correspond to the detection of either delocalized Ets-1 p51 protein or Ets-1 p27 isoform, whose expression may be increased in these situations. In spite of its weak expression, Ets-1 p27 may optimize its dominant-negative function, suggesting that Ets-1 p27 has a real biological effect. Furthermore, Ets-1 p27 may also increase its dominant-negative potential toward Ets-1 p51 through the sequestration of its partners that participate in Ets-1 p51 effects.
The dominant-negative function of Ets-1 p27 toward endogenous Ets-1 p51 is confirmed in the context of the MDA-MB-231 mammary carcinoma cells, because an increase in the Ets-1 p27/Ets-1 p51 ratio represses their tumoral properties (Figure 6 ). The biological relevance of this effect is supported by the fact that we detected Ets-1 p27 expression in vivo in breast adenocarcinomas (Figure 1c) . Surprisingly, the Ets-1 p27-encoded variant is highly expressed in fetal lung but not in adult lung (Figure 1d) . Therefore, it would be very interesting to assess the expression of Ets-1 p27 in lung carcinoma explants to determine if it is synthesized in these tumors. Owing to the implication of Ets-1 in various cellular mechanisms, the existence of this dual-acting dominantnegative isoform and its repressor effect on tumor cell properties suggests a determinant effect of the Ets-1 p27/Ets-1 p51 ratio on cell fate. ) was used to amplify ets-1 cDNAs after reverse transcription. PCR product corresponding to the shorter cDNAs was purified, cloned into pCR Blunt II-TOPO (Invitrogen, Carlsbad, CA, USA) and sequenced. Sequences are available in the GenBank database under accession number EU939724 for the rabbit sequence and AY943926 for the human sequence.
Materials and methods
Isolation
Retroviral infection
Retrovirus production and infection were performed using empty pLPCX (clone 1) or Flag-Ets-1 p27 pLPCX (clones 2 and 3) as previously described (Kherrouche et al., 2006) . After infection, MDA-MB-231 cells were selected with 1 mg/ml puromycin for 96 h and routinely cultured in the presence of 500 ng/ml puromycin.
Western blot analysis
Western blot analysis was performed as previously described (Baillat et al., 2006) using (1) 30 mg of total cell lysate proteins or (2) 25 ml of total cell lysates in the case of reporter gene assays, which were boiled in Laemmli buffer (50 mM Tris (pH 6.8), 2% sodium dodecyl sulfate, 5% b-mercaptoethanol, 10% glycerol, 0.1% bromophenol blue). Primary antibodies used (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were the C-20 anti-Ets-1, C-20 anti-Ets-2, 16 anti-PEA3, C-14 anti-Erk-2, H-79 anti-cJun and H-125 anti-cFos. The specific anti-Ets-1 p27 was produced (Eurogentec, Angers, France) in rabbit against an immunogen peptide (of the sequence ELFPSPGKLGG) designed at the alternative splicing junction.
Electrophoretic mobility shift assay Double-stranded synthetic oligonucleotides corresponding to the WT and mutants (M1, M2 and M1M2) of the human stromelysin-1 (À223/À193) promoter region were used to perform EMSA experiments as previously described (Laitem et al., 2008) . For probe competition, 400 ng of WT or M1M2 non-labeled probe (800 Â ) were added to the reaction mixture. For protein competition, Ets-1 p51 (4 pmol) was incubated with increasing quantity of recombinant Ets-1 p27 (0-15 pmol) with 0.5 ng of WT-labeled probe in the same conditions.
SPR-binding assay
Surface plasmon resonance measurements were carried out using a BIAcore 2000 apparatus (GE Healthcare, Waukesha, WI, USA), as previously described (Baillat et al., 2002) .
See Supplementary Information for Cell culture, RNA extraction and RT-PCR assays, eukaryotic expression vector constructions, bacterial expression vector constructions and recombinant protein production, reporter vector constructions, transient transfection, transfection and reporter gene Ets-1 p27, a dual-acting Ets-1 dominant negative C Laitem et al assay, immunofluorescence, growth assay, soft agar colony formation assay, invasion assay and xenograft in nude mice.
